Literature DB >> 12871129

Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects.

B Wirleitner1, G Neurauter, K Schröcksnadel, B Frick, D Fuchs.   

Abstract

Tryptophan is an essential amino acid and the least abundant constituent of proteins. In parallel it represents a source for two important biochemical pathways: the generation of neurotransmitter 5-hydroxytryptamine (serotonin) by the tetrahydrobiopterin-dependent tryptophan 5-hydroxylase, and the formation of kynurenine derivatives and nicotinamide adenine dinucleotides initiated by the enzymes tryptophan pyrrolase (tryptophan 2,3-dioxygenase, TDO) and indoleamine 2,3-dioxygenase (IDO). Whereas TDO is located in the liver cells, IDO is expressed in a large variety of cells and is inducible by the cytokine interferon-gamma. Therefore, accelerated tryptophan degradation is observed in diseases and disorders concomitant with cellular immune activation, e. g. infectious, autoimmune, and malignant diseases, as well as during pregnancy. According to the cytostatic and antiproliferative properties of tryptophan-depletion on T lymphocytes, activated T-helper type 1 (Th-1) cells may down-regulate immune response via degradation of tryptophan. Especially in states of persistent immune activation availability of free serum tryptophan is diminished and as a consequence of reduced serotonin production, serotonergic functions may as well be affected. Accumulation of neuroactive kynurenine metabolites such as quinolinic acid may contribute to the development of neurologic/psychiatric disorders. Thus, IDO seems to represent a link between the immunological network and neuroendocrine functions with far reaching consequences in regard to the psychological status of patients. These observations provide a basis for the better understanding of mood disorder and related symptoms in chronic diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871129     DOI: 10.2174/0929867033457179

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  53 in total

1.  Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis.

Authors:  Patricia A Zunszain; Christoph Anacker; Annamaria Cattaneo; Shanas Choudhury; Ksenia Musaelyan; Aye Mu Myint; Sandrine Thuret; Jack Price; Carmine M Pariante
Journal:  Neuropsychopharmacology       Date:  2011-11-09       Impact factor: 7.853

2.  Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human lens epithelial cells: apoptosis through the formation of 3-hydroxykynurenine.

Authors:  Maneesh Mailankot; Ram H Nagaraj
Journal:  Int J Biochem Cell Biol       Date:  2010-05-06       Impact factor: 5.085

Review 3.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

4.  Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis.

Authors:  Raghava Potula; Larisa Poluektova; Bryan Knipe; Jesse Chrastil; David Heilman; Huanyu Dou; Osamu Takikawa; David H Munn; Howard E Gendelman; Yuri Persidsky
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

5.  Immune system dysregulation in adolescent major depressive disorder.

Authors:  Vilma Gabbay; Rachel G Klein; Carmen M Alonso; James S Babb; Melissa Nishawala; Georgette De Jesus; Glenn S Hirsch; Pauline M Z Hottinger-Blanc; Charles J Gonzalez
Journal:  J Affect Disord       Date:  2008-09-13       Impact factor: 4.839

Review 6.  Pre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents.

Authors:  Andrew Schrepf; Susan K Lutgendorf; Leah M Pyter
Journal:  Brain Behav Immun       Date:  2015-05-06       Impact factor: 7.217

7.  Indoleamine 2,3-dioxygenase, tryptophan catabolism, and Mycobacterium avium subsp. paratuberculosis: a model for chronic mycobacterial infections.

Authors:  Karren M Plain; Kumudika de Silva; John Earl; Douglas J Begg; Auriol C Purdie; Richard J Whittington
Journal:  Infect Immun       Date:  2011-07-05       Impact factor: 3.441

8.  Differential effect of type I and type II interferons on neopterin production and amino acid metabolism in human astrocyte-derived cells.

Authors:  Oscar D Cano; Gabriele Neurauter; Dietmar Fuchs; Gene M Shearer; Adriano Boasso
Journal:  Neurosci Lett       Date:  2008-04-18       Impact factor: 3.046

9.  Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment.

Authors:  S J Bull; P Huezo-Diaz; E B Binder; J F Cubells; G Ranjith; C Maddock; C Miyazaki; N Alexander; M Hotopf; A J Cleare; S Norris; E Cassidy; K J Aitchison; A H Miller; C M Pariante
Journal:  Mol Psychiatry       Date:  2008-05-06       Impact factor: 15.992

Review 10.  Immunopathogenic mechanisms in tourette syndrome: A critical review.

Authors:  Davide Martino; Russell C Dale; Donald L Gilbert; Gavin Giovannoni; James F Leckman
Journal:  Mov Disord       Date:  2009-07-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.